According to the WHO, lung cancer is a major cause of cancer related deaths and KRAS is the most frequently mutated oncogene (nearly 17% of lung cancers) in human lung cancers. New work from MSU unveiled a novel avenue of targeting RAS directly to combat RAS-mediated tumourigenesis. We show that the small adaptor protein prohibitin is highly expressed in human NSCLCs and that targeting of prohibitin with chemical ligands prevents KRAS-mediated tumourigenesis. We further uncovered that rocaglamide, a plant derived anti –cancer drug and prohibitin ligand exhibits direct effects os RAS-GTP loading in cells. While targeting RAS was presumed to be invincible, this study opens up a novel avenue of targeting RAS directly. This work was performed in collaboration with Indivumed Gmbh, Hamburg and with the lab of Prof. Laurent Desaubry in CNRS/University of Strasbourg, France.
For the interactive PDF , please click the link below
https://www.nature.com/articles/onc201793.epdfauthor_access_token=6uZ59b2WUdjcvAN7uct00dRgN0jAjWel9jnR3ZoTv0NvNMRi1LkTYcxDH3gCxH5CwqyG0nC-K7_-ev84UuhugcIhxsWw_hA1R24Is7u0TRl5walTCtp1UEFZbSQKobEY